




Burns turned 100 years old.
In recent appearances in the
media, he still seems sharp as a
tack, and is still seen smoking his
trademark cigars. Others ofus, how-
ever, were never very funny, and would die
of cancer at age 60 if we continuously
smoked cigars or cigarettes. Burns presents
a common but perplexing paradox: some
people are able to tolerate at least moder-
ate exposure to toxins such as cigarette
smoke with little adverse affect, while oth-
ers develop cancer, emphysema, or heart
disease.
New studies support the idea that there
is an interaction between genes and the
environment, and that this interaction may
be an important determinant of cancer
risk. To understand such risks, it is essen-
tial to look at both an individual's genetic
makeup and environmental exposures.
Such studies require the collaboration of
molecular epidemiologists and molecular
biologists. At the NIEHS, JackA. Taylor, a
lead clinical investigator in the
Epidemiology Branch, and Douglas A.
Bell, an investigator with the Genetic Risk
Group of the Laboratory of Biochemical
Risk Analysis, have worked together and
with other scientists to uncover new infor-
mation in this area.
"Taylor and Bell each have unique tal-
ents that complement each other," says
Allen Wilcox, chief of the Epidemiology
Branch at the NIEHS. "Taylor provides an
JaCKA. Iaylor
understanding ofpopulation-based
research, and Bell is skilled at
developing the technical aspects of
gene assays. They both share an
intuition for connections that
might be made between toxic expo-
sures, genetic susceptibility, and cancer
riskinhumanpopulations."
Genes and environment may interact
in different ways to cause disease. In the
case of cancer, environmental exposures
may cause damage to critical genes
involved in cell growth and regulation,
thereby initiating cancer. This critical tar-
get gene damage is an example of direct
gene-environment interaction.
Genes and environment may interact
in other ways. The genes we inherit may
affect our ability to detoxify a chemical
exposure, or to repair DNA damage once it
occurs. Thus, variants ofcertain genes can
leave us more susceptible to cancer.
There are a large number of classes of
potential susceptibility genes, including
allelic variants in DNA repair and fidelity,
hormone receptors, cell growth, and car-
cinogenic metabolizers. These involve both
common and rare variants, and present
high and low risks ofdisease. Rare genetic
variants, such as BRCAI (implicated in
some breast and ovarian cancers), confer a
very high risk of a particular cancer, and
may occur in familial clusters. Other gene
variants produce much lower elevations in
cancer risk, but occur at much higher fre-
quencies in the population. Such genes
may be detected in population-based,
case-control studies. At low or moderate
exposure to carcinogens, individuals
possessing these variants show
increased risk.
The growing knowledge in this
field presents significant opportuni-
ties and challenges to individuals
concerned with safeguarding their
health, and to policy makers and
employers faced with evaluating risks
in the environment as well as the
workplace, and determining a course





began at the NIEHS with Taylor's
arrival in the mid-1980s. Taylor
took a particular interest in the
interaction between genes, the envi-
ronment, and bladder and lung can-
cer-the two types of cancer most
closely associated with environmen-
tal exposure.
"Animal data showed that exposure of
mice and rats to certain chemicals could
cause specific mutations in proto-onco-
genes, turning them into oncogenes,"
Taylor says. "I wanted to see if this
occurred in humans. So in 1986, I began
collecting tumors from people with high
occupational exposure to see what patterns
of mutation were caused in critical target
genes.
Over the next decade, Taylor directed a
variety ofstudies looking at genetic defects
in tumors from people with different expo-
sures. In studies of lung cancer, Taylor
examined populations exposed to uranium,
nickel, asbestos, vinyl chloride, and ciga-
rette smoke. Taylor's bladder cancer stud-
ies dealt with workers exposed to highly
carcinogenic arylamine, patients treated
with the chemotherapeutic agent
cyclophosphamide, and smokers and non-
smokers.
The laboratory phases of these studies,
carried out in collaboration with NIEHS
scientist Teddy Devereaux and molecular
biologists elsewhere, initially focused on
the mutational activation of ras family
oncogenes and deactivation of the tumor
suppresser genep53, both ofwhich appear
to be frequent early events in the genesis of
lung and bladder cancers. The studies on
lung tumors in uranium miners showed
that 32% oflarge and squamous cell can-
cers from miners had an identical mutation
in p53, while this mutation was very rare
in tumors from smokers. This rather sur-
prising result provides support for the idea
that different carcinogens may cause differ-
ent mutational "fingerprints," although
Taylor points out in a recent study that
such mutations do not occur in all types of
lung cancers in uranium miners.
Molecular epidemiology studies help
identify the pathways by which environ-
mental agents initiate tumors. At the same
time, the defects present in tumors may
help to reveal what types ofenvironmental
exposures are causing different cancers.
GeneticSusceptibility Studies
While conducting studies in critical target
genes, Taylor began another study
designed to look at genetic susceptibility
and gene-environment interaction in blad-
der cancer. In collaboration with urologists
at Duke University and the University of
North Carolina at Chapel Hill, he collect-
ed data from over 200 cases and 200 con-
trol subjects over a four-year period in the
late 1980s. Although methods for genotyp-
ing large populations were not well devel-
oped at the time and few genes had been
cloned, Taylor reasoned that by the time
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his study was out of the field, such tech-
niqueswouldbe available.
"We knew that both environmental
exposures and genetics were important to
bladder cancer risk, and I wanted to design
a study that looked at genetic susceptibility
and environmental exposures simultane-
ously," says Taylor. "That opportunity
camealongwhen DougBell arrived."
In 1990, Bell joined the NIEHS staff.
Bell knew how to rapidly done and iden-
tify mutations in metabolism genes using
a molecular genetic technique known as
polymerase chain reaction. Bell and
Taylor formed a collaboration to explore
the potential association between carcino-
gen metabolism gene polymorphisms and
risk in the samples Taylor had previously
collected.
Two dasses ofenzymes, the N-acetyl-
transferases (NATI and NAT2) and glu-
tathione-S-transferases (GSTMI and
GSTTI), play important roles in the
metabolism of carcinogens such as poly-
cydic aromatic hydrocarbons and aromatic
amines-carcinogens found in tobacco
smoke, air pollution, occupational expo-
sures, and dietary sources. These enzymes
are expressed only in certain tissues in the
body. For example, NAT2 is present pri-
marily in the liver, while NAT) is more
highly expressed in the bladder and colon.
Scientists have theorized that polymor-
phisms in such genes affect the efficiency
of activation or detoxification of environ-
mental carcinogens, and may play a role in
the development ofcancer in those organs.
In their first results, Bell and Taylor
Doqi A. Bell
showed that people who inherited two
defective copies of GSTMI had a twofold
increased risk ofbladder cancer compared
to people who inherited a functional copy
ofthe gene. Thepresence orabsence ofthe
gene only affected risk in people who were
smokers.
Previous studies had suggested that
NAT) might play an important role in the
metabolism of aromatic amines, carcino-
gens found in cigarette smoke and well-
cooked meats. Variations in NAT) activity
among human populations might affect
the risk of DNA damage in tissues and
subsequent risk ofbladder and colon can-
cer. Working with Fred Kadlubar, a
researcher with the National Center for
Toxicological Research, Bell found twofold
higher NATI enzyme activity in samples
from individuals who inherited a variant
polyadenylation signal known as the
NATP10 allele. This was the firstobserva-
tion to relate a genetic polymorphism in
NATI to a high-activity NAT) phenotype
in humans.
Next, Bell and Kadlubar sought to
determine how these polymorphisms
modulate DNA adduct formation in the
human bladder. Adducts mark the binding
of a chemical to DNA. They can cause
miscoding of DNA during replication,
which can subsequently lead to mutations
and cancer. This study compared levels of
aromatic amine-DNA adducts among
individuals with different NATI and
NAT2 genotypes. Individuals with the
rapid NAT) genotype (NATl*10 allele)
were found to have twice the aromatic
amine-DNA adducts compared to
those with the normal activity
NATI genotype. In addition, indi-
viduals with thecombined high-risk
genotypes for both NAT) and
NAT2had the highestlevel ofblad-
deradducts.
With this knowledge in hand,
Bell teamed up with Richard
Strange, a researcher from Keele
University in North Staffordshire,
England, to analyze a case-control
study of 202 colorectal patients to
determine if the NAT)*10 allele
increases the risk ofcolorectal can-
cer. The study found a 1.9-fold in-
creased riskofcancerassociatedwith
the NATl*10 allele. In contrast,
rapid acetylation genotypes of
NAT2 were found not to signifi-
cantly increase cancer risk in this
group. However, the study found
that the risk associated with
NATP*10 was most apparentamong
those with high risk NAT2 geno-
typcs, suggesting a possible gene-gene
interactionbetweenNAT) andNAT2.
Bell and Taylor have recendy collabo-
rated on a similar study to determine if
NAT) and NAT2play a role in the devel-
opment ofbladder cancers associated with
aromatic amine exposure. Results of this
study point to a positive association
between the NAT)*I0allele and increased
riskofbladdercancer.
In collaboration with NIEHS epidemi-
ologist Dale Sandier, Bell and Taylor have
also studied the impact of GSTMI and
GSTTI polymorphisms on the risk of
developing myelodysplastic syndromes
(MDS), anomalies of the spinal cord.
Hongwei Chen, a researcher in Bell's lab,
has found that individuals with two defec-
tive copies of the GSTTI gene are at a
fourfold riskofdevelopingMDS.
The work ofTaylor and Bell provides
further evidence that individuals vary in
their response to exposure to environmen-
tal chemicals. This knowledge should help
improve the accuracy of risk assessment
and allow preventative methods to be pre-
scribed for targeted individuals. Scientists
predict that within the next ten years it
will be possiblc to develop cancer-risk pro-
files for individuals. Such profiles can help
steer individuals away from certain envi-
ronmental agents, or may direct screening
ofthose individuals known to be at greatcr
risk.
JohnManuel






In December, NIEHS Diretor
Kenneth Olden announc th
appontment ofGoge LUi as
director of the in st':senvir-
onmental Toxicology Program
(ETP). Inmakingtheannounce-
ment Olden said, '[Lucier's]
unique breadth ofabiliuies-as a
scientist, administator, and edi-
tor along with his highly
focused ability to get tasks
accomplished make him an
I
If{ :
excellent choice for this key role in ensuring the health of the
American people."
Lucier, chiefofthe NIEHS Laboratory of Biochemical Risk
Analysis and co-editor-in-chief of Environmental Health
Perspectives, becameactingdirectorofthe ETP in 1993. The ETP
is the NIEHS component of the National Toxicology Program
(NTP) that coordinates toxicologyresech and testingwithin the
Deparunent ofHealth and Human Services. The NTP provides
toxicological evaluations on chemicals ofpublic health interest;
develops and validates improved (more sensitive and specific)
methods of performing such evaluations; generates scientific
information to strengthen the basis ofpublic health and industri-
al safety and regulatory decisions; and communicates NTP find-
ingsto stakeholders.
One of the major new initiatives of the NTP is to develop
strategies for poraing all relevant data indluding mechanis-
tic information, into toxicological evaluations. The NIERS
fundsapproximatelyone-third oftoxicologystudies worldwide.
Upon assuming the directorship, Lucier said he plans to
focus his energies on ensuring that the program's toxicological
testing provides the necessary data to strengthen the scientific
foundation ofriskassessments and to reduce uncertainties assoc-
ated with current risk assessment prctices. "This is best accom-
plishedwhen scientific information is availablefrom anumberof
sources, said Lucier, "including toxicology, mechanistic data,
human studies, and mathematical models.' Lucier said the pro-
gram will work with regulatory agencies to determine the infor-
maion needed to make appropriate risk ssment decisions.
In addition to continuing to integrate the ETP's activities
with other NIEHS research efforts, Lucier plans to direct efforts
to creating partnerships with industry and regulatory agencies to
develop and validate faster and less expensive testing methods
that vill enable more cheiicals to be tested. "Partnerships will
lessen the time needed to develop databases ofsufficient size to
validate new assays," said Lucier. "The first step in this direction
occurred February 9, in an NTP/industry meeting on the valida-
tion oftransgenic models intoxicitytestingheldatthe NIEHS."
Lucier joined the NIEHS in 1970 afterobtaining a BA from
Clark Universityand a PhD in agriculture from the University of
Maryland. He also serves as an adjunct professor at the
University ofNorth Carolina at Chapel Hill on the faculties of
biochemistry, nutrition, and toxicology.
May 27-31, 1996
Under the auspices of
University of Oporto, IPCS, WHO, EC.
This course will cover the whole field of neurotoxicology and include classifications of neurotoxic substances,
mechanisms and pathophysiology of neurotoxicity, clinical and functional diagnosis of neurotoxic diseases (includ-
ing toxicological, electrophysiological and neurobehavioral tests), and epidemiology of neurotoxic diseases.
Faculty: H.H. Schaumburg, MD P.S. Spencer, PhD M. Lotti, MD
Albert Einstein College of Medicine Center for Research on Occupational Institute of Occupational Medicine,
New York, USA and Environmental Toxicology University of Padua, Italy
Portland, OR, USA
Registration andfurther information:
Dr. Ana Paula Augusto, Curso Ciencias da Nutricao, University of Oporto,
4200 Porto, Portugal, FAX: 351-2-5504143
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